Vivos Revenue Jumps 20% Amid Widening Losses, SCN Acquisition

TL;DR

**Vivos is burning cash at an alarming rate despite revenue growth, making it a risky bet for short-term gains.**

AI Summary

Vivos Therapeutics, Inc. (VVOS) reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $13.619 million, up from $11.333 million in the prior year, a 20.17% increase. This growth was primarily driven by a substantial rise in service revenue to $7.726 million from $5.725 million, and product revenue to $5.893 million from $5.608 million. Despite revenue growth, the company's net loss widened considerably to $14.276 million for the nine months ended September 30, 2025, compared to a net loss of $8.309 million in the same period of 2024. This increased loss is largely attributable to a surge in general and administrative expenses, which climbed to $19.181 million from $13.531 million, and higher cost of sales at $6.065 million. The company also completed the acquisition of The Sleep Center of Nevada (SCN) in June 2025 for $6.0 million cash and 607,287 shares of common stock valued at $1.5 million, contributing to increased goodwill and debt. Cash and cash equivalents decreased from $6.260 million at December 31, 2024, to $3.087 million at September 30, 2025, reflecting significant cash used in operating and investing activities.

Why It Matters

Vivos Therapeutics' substantial revenue growth, particularly in service revenue, indicates increasing adoption of its Vivos Method and related services, which could be a positive signal for market penetration in the sleep apnea treatment space. However, the significantly widening net loss and increased debt from the SCN acquisition raise concerns about profitability and financial stability, potentially impacting investor confidence and future growth prospects. For employees, the acquisition of SCN suggests expansion, but the overall financial health could influence job security and compensation. Customers might benefit from expanded access to Vivos's treatments through acquisitions like SCN, but the company's ability to sustain operations and innovation is crucial for long-term patient care. Competitively, Vivos is trying to differentiate itself with a non-surgical, potentially curative approach to OSA, but its financial performance will dictate its ability to compete with established CPAP and surgical solutions.

Risk Assessment

Risk Level: high — The company's net loss significantly widened to $14.276 million for the nine months ended September 30, 2025, from $8.309 million in the prior year. Cash and cash equivalents decreased by $3.173 million during the nine months, ending at $3.087 million, while total liabilities surged to $23.112 million from $7.330 million, largely due to $8.379 million in long-term debt and $1.400 million in other liabilities related to the SCN acquisition.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate Vivos's ability to achieve profitability and manage its rapidly increasing debt load. A wait-and-see approach is advisable until there's clear evidence of improved financial efficiency and a path to positive cash flow, especially given the significant cash burn and widening losses.

Financial Highlights

debt To Equity

N/A

revenue

$13.619M

operating Margin

N/A

total Assets

N/A

total Debt

$8.379M

net Income

-$14.276M

eps

N/A

gross Margin

N/A

cash Position

$3.087M

revenue Growth

+20.17%

Revenue Breakdown

Key Numbers

• $13.619M — Total Revenue (Increased 20.17% for the nine months ended September 30, 2025, from $11.333M in 2024.)
• $14.276M — Net Loss (Widened significantly for the nine months ended September 30, 2025, from $8.309M in 2024.)
• $7.726M — Service Revenue (Increased from $5.725M for the nine months ended September 30, 2025.)
• $19.181M — General and Administrative Expenses (Increased from $13.531M for the nine months ended September 30, 2025.)
• $3.087M — Cash and Cash Equivalents (Decreased from $6.260M at December 31, 2024, to September 30, 2025.)
• $8.379M — Long-term Debt (Increased from $0 at December 31, 2024, to September 30, 2025, primarily due to SCN acquisition financing.)
• $5.135M — Cash Payment for Acquisition (Net payment for The Sleep Center of Nevada acquisition in June 2025.)
• 8,988,106 — Common Stock Shares Outstanding (As of November 14, 2025, indicating dilution.)

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Registrant
• The Sleep Center of Nevada (company) — Acquired entity
• Nasdaq Capital Market (regulator) — Exchange where VVOS is listed
• $13.619 million (dollar_amount) — Total revenue for nine months ended September 30, 2025
• $14.276 million (dollar_amount) — Net loss for nine months ended September 30, 2025
• $6.0 million (dollar_amount) — Cash payment for SCN acquisition
• 607,287 (dollar_amount) — Shares of common stock issued for SCN acquisition
• $1.5 million (dollar_amount) — Value of common stock issued for SCN acquisition
• $3.087 million (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $23.112 million (dollar_amount) — Total liabilities as of September 30, 2025

FAQ

Risk Factors

• Widening Net Loss and Cash Burn [high — financial]: The company's net loss for the nine months ended September 30, 2025, increased to $14.276 million from $8.309 million in the prior year. This widening loss, coupled with a decrease in cash and cash equivalents from $6.260 million to $3.087 million, indicates a significant cash burn rate that could impact future operations.
• Integration Risk of SCN Acquisition [medium — operational]: The acquisition of The Sleep Center of Nevada (SCN) for $6.0 million cash and $1.5 million in stock introduces integration challenges. Failure to effectively integrate SCN's operations could hinder the realization of expected synergies and negatively impact financial performance.
• Increased Debt Load [medium — financial]: The company's long-term debt increased from $0 to $8.379 million, primarily due to financing for the SCN acquisition. This increased leverage raises financial risk and could strain cash flow due to debt servicing obligations.
• Dependence on Key Personnel and Services [medium — operational]: The company's revenue is heavily reliant on its proprietary treatment protocols and the services provided by its network of providers. Any disruption in the availability or effectiveness of these services or key personnel could materially impact revenue and profitability.
• Healthcare Regulatory Environment [medium — regulatory]: As a healthcare company, Vivos Therapeutics is subject to extensive and evolving federal and state regulations, including those related to medical devices, patient privacy (HIPAA), and healthcare fraud and abuse. Non-compliance could result in significant penalties and reputational damage.
• Dilution from Stock Issuance [low — financial]: The issuance of 607,287 shares for the SCN acquisition, in addition to the existing 8,988,106 shares outstanding as of November 14, 2025, indicates potential for significant shareholder dilution, impacting the value of existing shares.

Industry Context

Vivos Therapeutics operates in the rapidly growing sleep disorder treatment market, particularly focusing on non-CPAP solutions. The industry is characterized by increasing awareness of sleep apnea's health implications and a demand for innovative treatments. Competition includes established medical device companies and emerging biotech firms offering alternative therapies.

Regulatory Implications

The company must navigate stringent healthcare regulations, including FDA approvals for devices, HIPAA compliance for patient data, and anti-kickback statutes. Any misstep in regulatory compliance could lead to significant fines, legal challenges, and reputational damage, impacting market access and growth.

What Investors Should Do

1. Monitor G&A expense control: The substantial increase in G&A is a key driver of the widening net loss and needs to be scrutinized for efficiency improvements.
2. Assess SCN integration progress: Track the performance and integration of The Sleep Center of Nevada to ensure the acquisition delivers expected value and doesn't become a drag on financials.
3. Evaluate cash burn rate: With cash reserves significantly depleted, investors should assess the company's runway and future financing needs.
4. Analyze debt servicing capacity: The new long-term debt of $8.379M requires careful monitoring of the company's ability to service this obligation amidst its operating losses.

Key Dates

• 2025-09-30: Nine Months Ended — Reporting period for the 10-Q, showing significant revenue growth but a widening net loss and reduced cash.
• 2025-06-01: Acquisition of The Sleep Center of Nevada (SCN) — Major strategic move that increased assets, goodwill, and debt, but also introduced integration risks and cash outflow.
• 2024-12-31: Year-End — Baseline for comparison; cash position was $6.260M and long-term debt was $0.

Glossary

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. It represents the future economic benefits arising from assets acquired in a business combination that are not individually identified and separately recognized. (Increased due to the SCN acquisition, indicating the premium paid over the fair value of SCN's net assets.)

Cash Equivalents

Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. (The decrease in cash and cash equivalents from $6.260M to $3.087M highlights the company's cash burn and funding needs.)

General and Administrative Expenses (G&A)

Costs incurred for the general management of a business, including expenses for executive salaries, accounting, legal services, and office rent. (The significant increase in G&A expenses to $19.181M is a primary driver of the widened net loss.)

Cost of Sales

The direct costs attributable to the production or purchase of the goods sold by a company during a period. For services, it includes direct labor and overhead costs. (The increase in cost of sales to $6.065M, outpacing product revenue growth, suggests potential margin pressure on products.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Vivos Therapeutics has demonstrated robust revenue growth of 20.17%, driven by both service and product segments. However, this top-line expansion has been overshadowed by a significant widening of the net loss, primarily due to a substantial increase in General and Administrative expenses and higher Cost of Sales. The company's cash position has also declined considerably, reflecting increased operational and investing cash outflows, including the recent acquisition of SCN, which also introduced new long-term debt.

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share VVOS Nasdaq Capital Mark

Filing Documents

• form10-q.htm (10-Q) — 1160KB
• ex31-1.htm (EX-31.1) — 16KB
• ex31-2.htm (EX-31.2) — 16KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• 0001493152-25-024253.txt ( ) — 6344KB
• vvos-20250930.xsd (EX-101.SCH) — 49KB
• vvos-20250930_cal.xml (EX-101.CAL) — 71KB
• vvos-20250930_def.xml (EX-101.DEF) — 196KB
• vvos-20250930_lab.xml (EX-101.LAB) — 381KB
• vvos-20250930_pre.xml (EX-101.PRE) — 310KB
• form10-q_htm.xml (XML) — 966KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 43 Item 4.

Controls and Procedures

Controls and Procedures 43 PART II. OTHER INFORMATION 44 Item 1.

Legal Proceedings

Legal Proceedings 44 Item 1A.

Risk Factors

Risk Factors 45 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49 Item 3. Defaults Upon Senior Securities 49 Item 4. Mine Safety Disclosures 49 Item 5. Other Information 49 Item 6. Exhibits, Financial Statement Schedules 49

Signatures

Signatures 50 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Report") contains "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that reflect our current expectations and views of future events. The forward-looking statements are contained principally in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations." Readers are cautioned that known and unknown risks, uncertainties and other factors, including those over which we may have no control and others listed in this Report and our other public filings, may cause our actual results, performance or achievements to be materially different from those expressed or implied by the

forward-looking statements

forward-looking statements. You can identify some of these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. We have based these forward-looking results of operations, business strategy and financial needs. These forward-looking statements include statements relating to: our ability to continue to refine and execute our evolving business plan, including establishing and growing our new sales, marketing and distribution model where we acquire or create contractual alliances with operators of sleep testing and treatment centers as a means of driving sales of our appliances, including our June 2025 acquisition of The Sleep Center of Nevada ("SCN"); our ability to implement and grow our sales, marketing distribution model, which is new and unproven and may not produce the benefits we anticipate; our ability to successfully integrate SCN business into our operations; our ability to service the substantial indebtedness we incurred in connection with financing the SCN acquisition; compliance with laws, rules and regulations relating to the corporate practice of medicine; the acceptance and adoption by dentists, sleep specialists, medical doctors and other healthcare professionals of our proprietary oral appliances as a treatment for dentofacial abnormalities and/or mild to severe obstructive sleep apnea ("OSA") and snoring in adults and moderate to severe OSA in children ages 6-17 as per our U.S. Food and Drug Administration (or "FDA") clearances; our expectations concerning the effectiveness and duration of treatment using our appliances and protocols (which we refer to as The Vivos Method) and the potential for side effects including, but not limited to, patie

View Full Filing

View this 10-Q filing on SEC EDGAR